Dr. Cella on Patient-Reported Outcomes in a Clinical Setting

Article

Dr. David Cella from Northwestern University Feinberg School of Medicine on Patient-Reported Outcomes in a Clinical Setting

David Cella, PhD, a clinical research specialist and chair of the Department of Medical Social Science at Northwestern University Feinberg School of Medicine in Chicago, discusses that tests, similar to the functional assessment of cancer therapy kidney symptom index-15 (FKSI-15) used in his phase III AXIS trial comparing axitinib to sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC), are available to clinical use for quality-of-life assessments and are being widely validated. The FKSI-15 test examines 15 areas that were rated as relatively important out of 34 reported symptoms of mRCC.

Recent Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.